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ABSTRACT: 
Recent studies have demonstrated an association between higher body mass index and increased 
aggressiveness in prostate cancer.  
The present narrative review, based on a search of Medline® and Embase® databases from 
October 1982 to October 2012, explores the relationship between higher body mass index and 
localized prostate cancer. In particular, the current epidemiological and mechanistic evidence for 
interactions between obesity and prostate cancer are discussed. 
Obesity is associated with alterations in androgen levels, decreased sex hormone binding 
globulin and increased estrogen levels, insulin resistance, hyperglycemia, alterations in plasma 
lipoprotein  levels  particularly  raised  triglycerides  and  reduced  high  density  lipoprotein, 
decreased  levels  of  adiponectin,  and  increased  levels  of  circulating  insulin-growth  factor-  1, 
leptin and dietary saturated fats. Obese men have more aggressive prostate cancer with a greater 
percentage prostate involvement, increased tumor volume and higher-grade disease, enlarged 
prostates, high prostate-specific antigen levels, increased risk of having positive margins and 
recurrence.  
Moreover,  there  is  strong  evidence  of  the  beneficial  effects  of  functional  foods  for  the 
treatment of obesity. Additionally, an increasing number of studies support that obesity-induced 
inflammation plays an important role in the development of obesity-related pathologies. Despite, 
the beneficial role of nutriment in prostate cancer control, the use of functional foods in prostate 
cancer is not recommended for lack of large epidemiological studies.   
This data supports the hypothesis that obese men have more aggressive prostate cancers and 
that the obesity is a modifiable risk factor of prostate cancer.  
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Prostate cancer is now recognized as a major public health issue affecting western countries. It 
remains the most common malignancy and the second-leading cause of cancer deaths among 
men in the USA, with an estimated 218,890 new cases and 27,050 deaths in 2007 in the USA [1]. 
In  Europe,  with  an  incidence  rate  of  214  cases  per  1000  men,  prostate  cancer  is  the  most 
common solid neoplasm, exceeding lung and colorectal cancer [2]. Additionally, since 1985, 
there has been a slight increase in most countries in the number of deaths from prostate cancer, 
even in countries or regions where prostate cancer is uncommon [3].  
Rates of obesity, a condition defined as having “excessive body fat”, have risen alarmingly 
over the last decade with approximately one in three adults in the United States being considered 
obese  as  compared  to  one  in  six  20  years  ago[4].  Excess  body  weight  is  associated  with 
increased risk of cancer at several organ sites, including colon, breast, endometrium, esophagus 
and prostate. From a biological perspective, one can put forth a number of potential mechanisms 
by which obesity might promote prostate cancer and/or prostate cancer progression, including: 
reduced levels of testosterone, increased levels of estrogen, co-existence of diabetes or metabolic 
syndrome, increased levels of circulating insulin-growth factor-one (IGF-1), increased levels of 
leptin, decreased levels of adiponectin and increased dietary saturated fats [5]. 
The increase in the incidence of prostate cancer is related to prostate-specific antigen (PSA)-
based screening [6]. That the identification of risk factors for aggressive prostate cancer allows 
better treatment options for patients is now well established [7]. Obesity currently represents one 
of  these  risk  factors.  In  fact,  increasing  recent  evidence  is  tending  towards  an  association 
between  obesity  and  more  aggressive  prostate  cancer,  increased  risk  of  high-grade  prostate 
cancer and prostate cancer mortality but also possibly a reduced risk of low-grade prostate cancer 
[8]. Obese men have a greater risk of adverse pathological features and biochemical recurrence 
after  radical  prostatectomy.  The  higher  BMI  was  found  to  be  associated  with  a  greater 
percentage of prostate involvement [9], increased tumor volume, higher-grade disease [9, 10] 
and enlarged prostates [11, 12]. Additionally, obese men undergoing radical prostatectomy were 
shown to have an increased risk of positive margins [13], higher initial PSA with increased risk 
of recurrence [14], increased risk of upgrading prostate cancer [15] and higher risk of advanced 
prostate cancer [16]. Metabolic disorders such as diabetes and obesity, as well as metabolic 
syndrome have been shown in population-based and experimental studies to modulate prostate 
cancer risk and aggressiveness.  
OBJECTIVE:  The  purpose  of  the  present review  was  to assess  the  impact of  obesity 
on prostate cancer in men. In this review the current epidemiological and mechanistic evidence 
regarding the interactions between obesity and prostate cancer will be discussed. 
 
METHODS: 
Published literature on the relationship between obesity and prostate cancer was obtained using a 
Pubmed® search limited to English language studies and critically reviewed. The following key-
words  were  used:  prostate  cancer,  obesity,  high  BMI,  recurrence  and  survival,  biological 
alterations. 
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Definition  and  physiopathology  of  obesity:  According  to  the  World  Health  Organization 
(WHO) and the National Institutes of Health (NIH), overweight is defined as a body mass index 
(BMI) over 25 kg/m2 and obesity as over 30 kg/m2. BMI is easy to use but other definitions 
have been proposed in the literature including waist-to-hip ratio (WHR), body fat percentage, 
skin fold thickness, crude weight, and lean body mass [17].  
A disproportionate amount of body fat within the abdominal cavity, otherwise known as 
visceral obesity, best predicts the negative health outcomes associated with high levels of body 
fat. Abdominal fat distribution is associated with several metabolic and hormonal derangements 
including  decreased  levels  of  sex  hormone  binding  globulin  (SHBG),  decreased  levels  of 
testosterone, increased levels of estrogen, insulin resistance, hyperglycemia, and alterations in 
levels of plasma lipoprotein particularly increased triglyceride and decreased HDL. Abdominal 
obesity is associated with an increased risk of heart disease and diabetes and recent studies have 
also looked into its relationship with prostate health [18]. 
Recent data support the hypothesis that the hormonal environment in overweight and obese 
men  may  alter  androgen-dependent  prostate  growth.  Body  mass  index  (BMI)  has  been 
implicated in prostate cancer pathology [19]. 
 
Biological alterations associated with obesity and involved in prostate pathology: Recent 
studies  have  shown  that  obesity  is  associated  by  multiple  biological  alterations  that  are 
potentially involved in the aggressiveness of prostate cancer (Table 1). Of these anomalies, we 
can mention [5]: alterations in androgen levels, decreased levels of SHBG, increased levels of 
estrogen,  insulin  resistance,  hyperglycemia  (co-existing  diabetes  or  metabolic  syndrome), 
alterations in levels of plasma lipoprotein particularly increased triglyceride and decreased HDL, 
decreased levels of adiponectin, and increased levels of circulating IGF-1, leptin and dietary 
saturated fats [5]. 
 
Androgens,  SHBG and obesity:  According to several epidemiological studies, high BMI is 
associated with decreased serum testosterone. However, the mechanisms of obesity-associated 
hypogonadism are complex. Epidemiological studies support a bidirectional relationship between 
serum  testosterone  and  both  obesity  and  metabolic  syndrome  [20].  In  fact,  hypogonadism 
predicts central obesity and intra-abdominal fat accumulation [21]. Additionally, lowering serum 
testosterone levels with androgen deprivation therapy in older men with prostate cancer increases 
body fat mass [22].  
In  obese  men,  levels  of  total  testosterone,  bioavailable  testosterone,  diurnal  luteinizing 
hormone and SHBG are reduced [23].  In addition high BMI, central adiposity and metabolic 
syndrome are associated with and predict low serum total and to a lesser extent free testosterone 
and SHBG levels [24]. The obese men have what is called relative hypogonadism that increases 
the  aggressiveness  of  prostate  cancer  [25].  Androgens  are  involved  in  prostate  growth  and 
malignant transformation [19] though the exact mechanisms of action are poorly understood and 
are the subject of some controversy. Metabolic factors and androgens  may promote prostate 
carcinogenesis via multiple mechanisms  including inflammation,  adipokine action, fatty  acid 
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The low total testosterone or SHBG levels are also associated with type 2 diabetes, which is 
another  risk  factor  of  prostate  cancer  [26].  Also,  low  SHBG  was  found  to  be  a  strong 
independent predictor of type II diabetes [27]. 
Estrogen and obesity: Obese men have been shown to have increased levels of estrogen [28]. 
Animal model-based studies have suggested that the estrogens may originate from aromatized 
androgens and act with estrogen metabolites to cause prostate cancer [25]. While the androgen-
receptor  mediated  activity  of  androgens  and  estrogen  receptor-mediated  effects  of  estrogen 
metabolites are likely necessary, estrogen genotoxicity appears to be a probable critical factor [5, 
29].  
 
Table 1: Biological abnormalities observed in obese men may be involved in the mechanism of 
prostate cancer. 
 
Authors, year[ref.]  Study design  n  Principal findings 
Brand et al., 2011[21]  Meta-analysis of 
observational 
studies 
22 043  The presence of a sex-dependent association 
between  testosterone  and  metabolic  syndrome: 
total  testosterone  and  free-testosterone  levels  are 
lower in men with metabolic syndrome, whereas 
they  are  higher  in  women  with  metabolic 
syndrome.  There  are  no  indications  for  a  sex-
specific association between SHBG and metabolic 
syndrome.  In  both  men  and  women,  metabolic 
syndrome is associated with lower SHBG levels. 
Dandona  et  al,  1998 
[31] 
Prospective study  38   Increased  cytokines:  TNF-a  and  IL-6,  both 
are  inflammatory  cytokines,  released  by  adipose 
tissue stimulated by inflammatory stimuli. Serum 
concentration of IL-6 and TNF-a are increased in 
high  BMI  and  weight  loss  results  in  decreased 
levels  
Vikan et al., 2010, [28]  Population-based 
prospective cohort 
study 
1 454  Men  with  higher  estradiol  levels  had  an 
increased  risk  of  later  diabetes  independent  of 
obesity,  while  men  with  lower  total  testosterone 
and SHBG had an increased risk of diabetes that 
appeared  to  be  dependent  on  obesity.Low 
testosterone and SHBG levels and high estradiol 
levels are independent predictors of type 2 diabetes 
in men. 
 
Cytokines and obesity: The pro-inflammatory cytokines, IL-6 and TNF-a, released by adipose 
tissue in response to inflammatory stimuli, and resistin are all adipokines that antagonize the 
action of insulin [30]. Serum concentrations of IL-6 and TNF-a are increased in high BMI and 
decreased  following  weight  loss  [31].  Additionally,  the  high  levels  of  IL-6,  TNF-alpha  and 
resistin associated with obesity provoke insulin resistance. Such insulin resistance is associated 
with high risk of prostate cancer via both the obesity-sex hormone pathway [32] and non-insulin 
related  pathway  [33].  Insulin  antagonizing  adipokines  are  associated  with  prostate  cancer 
aggressiveness. The levels of IL-6 are increased in obese prostate cancer patients and may have a 
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protein, are not only lower in obesity but are also negatively associated with histological grade 
and stage of disease in prostate cancer [14]. 
 
Obesity  and  prostate  cancer:  The  higher  BMI  of  obese  patients  with  prostate  cancer  is 
associated  with  a  greater  percentage  of  the  prostate  involvement,  increased  tumor  volume, 
higher-grade  disease  and  enlarged  prostates.  Additionally,  obese  men  undergoing  radical 
prostatectomy have an increased risk of positive margins, recurrence, high initial PSA, upgrading 
prostate cancer and advanced prostate cancer (Table 2). 
Several epidemiological studies suggest greater body adiposity may be a modifiable risk 
factor for high-grade (Gleason 7, Gleason 8-10) prostate cancer and prostate cancer mortality. 
 
Obesity and PSA: Studies on the impact of high BMI on PSA levels are controversial. Indeed, 
increased BMI, high insulin and type II diabetes mellitus were found associated with increased 
prostate volume but, paradoxically, with lower PSA levels [35]. Grubb et al. suggested that the 
inverse relationship between obesity and PSA, in spite of a larger prostate volume, could be the 
result of hemodilution in larger plasma volumes among obese men [36]. Recently, Mitchell et al. 
[37] reported that the BMI does not affect the association between the PSA level and tumor 
volume. 
Conflicting results were found in a retrospective study carried out by our group on 464 
patients  with  localized  prostate  cancer  who  had  undergone  radical  prostatectomy  [38].  We 
reviewed  preoperative  BMI  and  whole  prostate  weight  and  used  multivariable  regression 
modeling adjusting for age, year of surgery, preoperative serum PSA, pathological stage and 
Gleason  grade.  In multivariable regression, preoperative BMI was  positively  associated with 
increasing prostate weight (p=0.000000) and higher initial PSA (p=0.00000). 
 
Obesity and radical prostatectomy for cancer: Mitchell et al. studied a population of 14,293 
patients and found that at the time of prostatectomy for prostate cancer, obese patients have 
worse pathological features.  
Using  the  clinicopathologic  variables,  they  examined  the  relationship  among  the  BMI, 
preoperative  PSA  level,  and  tumor  volume  at  radical  prostatectomy  using  multiple  linear 
regression analysis. Elevated BMI was associated with an increased pathologic Gleason score (P 
< .0001), increased tumor volume (P  < .0001), and increased prostate  size (P  < .0001) and 
additionally, the preoperative PSA level correlated significantly with the tumor volume (P < 
.0001) [37]. 
Concordantly, our study cited above [38] on obese men undergoing radical prostatectomy 
found a higher biopsy Gleason score (p=0.019833), higher final Gleason score (p=0.00000) with 
increased risk of upgrading prostate cancer (0.00000). Findings of previous studies have found 
that obesity is related to an increased risk of high-grade prostate cancer and prostate cancer 
mortality but also possibly to a reduced risk of low-grade prostate cancer [8]. Amling et al [39] 
and  Freedland  et  al  [14]  reported  obesity  (BMI  greater  than  30  mg/kg2  and  35  mg/kg2, 
respectively) as being associated with higher grade tumors and higher rates of disease recurrence 
after  treatment  with  radical  prostatectomy,  and  Rodriguez  et  al  [39]  found  a  statistically 
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Capitanio  et  al.  [40]  analyzed  the  results  of  1,275  patients  with  prostate  cancer  who 
underwent radical prostatectomy at a single tertiary care institution, and found that obese men 
had a high tumor volume which correlated with BMI on univariable analysis (P < 0.001). On 
multivariable analysis, the BMI reached the independent predictor status after adjustment for 
age, PSA value, biopsy Gleason score, clinical stage and prostate volume (P= 0.03). 
 
Table 2: Recent clinical studies evaluated the relationship between obesity and prostate cancer.  
 
One study on 1,106 men undergoing radical prostatectomy between 1988 and 2002 showed 
the doubling in the percentage of obese men in the last 10 years. Obesity was associated with 
Authors, year [ref.]  Study design  n  Principal findings 
Capitanio et al., 
2012 [40]  
 
Retrospective 
single-center 
study 
1 275  Obese men have high tumor volume and, on univariable 
analysis,  BMI  was  correlated  with  tumor  volume  at 
radical  prostatectomy.  On  multivariable  analysis,  BMI 
reached the independent predictor status after adjustment 
for age, prostate-specific antigen value, biopsy Gleason 
score, clinical stage and prostate volume. 
De Nunzio et al., 
2011[49] 
Prospective 
single-center 
study 
885  Obesity is associated with an increased risk of a high-
grade Gleason score when prostate cancer is diagnosed at 
biopsy. 
Freedland et al., 
2004 [14] 
Retrospective 
single-center 
study 
1 106  Obesity is associated with higher-grade tumors, a trend 
toward increased risk of positive surgical margins, and 
higher biochemical failure rates among men treated with 
RP. A BMI > or = 35 kg/m(2) was associated  with a 
higher  risk  of  failure  than  a  BMI  between  30  and  35 
kg/m(2). 
Goris Gbenou et al., 
2012[38] 
Retrospective 
single-center 
study 
464  Obesity  is  associated  with  high  prostate  weight, 
increasing risk of upgrading prostate cancer and higher 
initial PSA 
Kopp et al., 
2011[11] 
Retrospective 
single-center 
study 
16 325  Preoperative BMI is associated with increased prostate 
weight. Compared with men with BMI < 25 kg/m(2) , 
men  with  a  BMI  ≥35  kg/m(2)  had  a  40%  (odds  ratio 
1.40, 95% CI 1.01-1.95) increased risk of prostate weight 
of at least 40 g and a 70% (odds ratio 1.70, 95% CI 1.32-
2.20) increased risk of prostate weight of at least 50 g. 
Mitchell et al., 2011 
[37] 
Retrospective 
single-center 
study 
14 293  Obesity is associated with increased pathologic Gleason 
score,  increased  tumor  volume  and  increased  prostate 
size. The preoperative PSA level correlated significantly 
with the tumor volume. 
   No significant correlation was found between the BMI 
and  preoperative  PSA  level.  On  multivariate  analysis, 
controlling  for  the  BMI,  the  preoperative  PSA  level 
remained  a  significant  predictor  of  the  tumor  volume. 
The interaction between the preoperative PSA level and 
BMI  in  the  prediction  of  the  tumor  volume  was  not 
statistically significant, suggesting that the BMI does not 
affect the association between the PSA level and tumor 
volume 
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higher-grade  tumors,  a  trend  toward  increased  risk  of  positive  surgical  margins,  and  higher 
biochemical failure rates among men treated with radical prostatectomy. A BMI ≥ 35 kg/m(2) 
was associated with a higher risk of failure than a BMI between 30 and 35 kg/m(2) [14].  
 
High BMI and prostate cancer recurrence and mortality: In their study on 2,131 patients 
undergoing  radical  prostatectomy  Basset  et  al.  [41]  found  that  obesity  (BMI  >  35  mg/kg2) 
increased the risk of prostate cancer recurrence by comparison with moderately obese to non-
obese men. However, after prostatectomy, BMI did not appear to be an independent predictor of 
recurrence or survival. Giovannucci et al. [42] reported the negative impact of adolescent obesity 
on overall health status. 
Several studies conducted over the last decade have demonstrated the negative impact of 
obesity on cancer recurrence and mortality. Calle et al, [43] reported a 20-30% higher risk of 
dying from prostate cancer in men who were overweight or obese or who had raised PSA at 
diagnosis  and  biochemical  failure.  Strom  et  al  [44]  found  that  the  risk  of  such  biochemical 
recurrence  was  higher  among  obese  patients  with  prostate  cancer.  Using  a  community  and 
academic based registry of 2,131 patients who underwent radical prostatectomy, Amling et al. 
[45] reported obesity as being associated with higher grade tumors and higher rates of disease 
recurrence after treatment 
Kopp  et  al.  [11]  examined  preoperative  BMI  and  whole  prostate  weight  in  a  cohort  of 
16,325 patients  undergoing radical  prostatectomy  for localized prostate cancer from  1975 to 
2008 at a single institution. In this US study, the authors demonstrated that preoperative BMI 
was associated with increased prostate weight. Compared to men with BMI < 25 kg/m(2), those 
with a BMI ≥35 kg/m(2) were at a 40% higher risk of their prostate weighing over 40g (odds 
ratio 1.40, 95% CI 1.01-1.95) and a 70% higher risk of it being over 50 g (odds ratio 1.70, 95% 
CI 1.32-2.20). 
 
Obesity: modifiable risk factor of prostate cancer: As demonstrated above, many studies have 
shown that obesity is a risk factor for aggressive prostate cancer. Measures do however exist to 
reduce BMI, in contrast with other and non-modifiable risk factors of prostate cancer. Mounting 
evidence that reducing BMI may improve parameters influencing prostate cancer is positive. 
Reduced caloric intake leading to significant weight loss increases SHBG levels regardless of 
diet composition [46]. A review by Raben and Richelsen [47] showed that the use of artificial 
sweeteners to replace sugar, especially in beverages, can be a useful aid to maintain reduced 
energy  intake  and  body  weight  and  decrease  the  risk  of  type-2  diabetes  and  cardiovascular 
disease. The authors concluded that dietary effects on circulating SHBG, and possibly also on 
androgens, can be expected if body weight or fatness and/or insulin homeostasis are modulated. 
Additionally, bariatric surgery can positively influence biological alterations affecting obese 
men  with  prostate  cancer.  In  an  observational  study  of  morbidly  obese  males  undergoing 
bariatric  surgery,  Pellitero  et  al  [48]  demonstrated  that  the  obesity-associated  hypogonadism 
highly prevalent in such a population is mostly reversed after sustained weight loss following 
surgery. 
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Dietary  patterns  and  management  of  obesity  and  prostate  cancer  using  functional  or 
medical foods and bioactive compounds  
Dietary,  functional  foods  and  prostate  cancer:  There is  strong  evidence of the beneficial 
effects of functional foods for the treatment of obesity. However, the use of functional foods in 
prostate cancer is still premature for lack of large epidemiological studies [50]. Currently, solid 
evidence exists regarding diet and prostate cancer particularly when patients achieving healthful 
body  weight  through  regular  exercise  and  consuming  a  healthful  plant-based  regime  rich  in 
fruits,  vegetables  and  complete  grains.  We  have  few  studies  focusing  specifically  in  use  of 
functional  foods  or  supplements  for  cancer  control.  In  fact,  numerous  studies  with  poor 
evidence-based medicine have been conducted on prostate cancer control and functional foods 
(e.g., soy and flaxseed), vitamins (e.g., vitamins D and E), micro-nutriments (e.g., selenium) and 
other food-related constituents (e.g., lycopene) [51].  
Vitamin D has been presented to reduce cellular proliferation, increase apoptosis and inhibit 
invasion,  migration, metastasis and angiogenesis [52,53].  The potential role of vitamin D in 
prostate  tumor  growth  and  aggressiveness  is  supported  by  environmental  and  case-control 
studies demonstrating an inverse relationship between prostate cancer mortality and advanced 
disease  with  ultraviolet  (UV)  exposure,  which  is  the  primary  source  of  vitamin  D  [54–57]. 
Additionally, African Americans and older men who have reduced capacity for absorbing UV, 
presented an increased prostate cancer mortality [58–59]. Calcitriol, a vitamin D analog, had 
positive action as therapeutic agents for patients with castrate-resistant prostate cancer reduction 
in  prostate-specific  antigen  levels  and  increasing  patient  survival,  however  the  problem  of 
avoiding hypercalcemia has not been overcome [60,61]. 
Primarily through the SELECT (Selenium and Vitamin E Cancer Prevention Trial) study, 
selenium and vitamin E have been shown to be beneficial for prostate cancer control. These 
supplements currently have no interest [62]. In addition, observational data from the Prostate, 
Lung,  Colorectal,  and  Ovarian  (PLCO)  Cancer  Screening  Trial,  which  includes  29,361  men 
monitored for prostate cancer, indicate no relationship between the risk or progression of prostate 
cancer and dietary or supplemental intakes of vitamins E and C or beta-carotene [63]. Results of 
a RCT of 540 head and neck patients receiving radiotherapy and randomized to 400 IU/day of 
vitamin  E  or  placebo  with  6.5-year  median  follow-up  show  significantly  higher  all-cause 
mortality in those taking vitamin E (HR=1.38, 95% CI 1.03–1.85), and increased cause-specific 
mortality [66]. 
Clark et al. reported findings of phase I-II trial that has analysed the impact of lycopene 
supplementation  on  biochemically-recurrent  prostate  cancer  in  36  patients  after  definitive 
localized treatment [64]. Results of this small trial suggest that doses of lycopene from 15–90 mg 
per day were not associated with detectable changes in PSADT.  
Chan et al. [65] have conducted a study on the impact of diet on risk of cancer progression 
in a cohort of 1,202 men diagnosed with incident localized/regional prostate cancer between 
1986 and 1996. Men completed prospective dietary surveys before and after diagnosis and were 
followed  through  2000.  Authors  examined  post-diagnostic  consumption  of  red  meat,  grains, 
vegetables, fruits, milk, tomatoes, tomato sauce, and fish as predictors of progression. In this 
study, they found significant protective associations for fish and tomato sauce, with Hazards 
Ratios (HR) of 0.52 (p=0.006) and 0.46 (p=0.04) for each daily serving increase, respectively. Functional Foods in Health and Disease 2013; 3(4):80-93                                                                    Page 88 of 93 
Additionally, “moderate,” but non-significant protective associations were found for vegetable 
consumption. In contrast, milk was found to increase risk for progressive disease (HR=1.12; 
p=0.04  for  each  daily  serving).  Interestingly  and  in  contrast  to  tomato  sauce,  raw  tomato 
consumption also was significantly associated with risk; a HR of 1.27 (p=0.02) was observed for 
each daily serving of raw tomatoes. While the inconsistency regarding tomato consumption is 
difficult to resolve, the authors attribute it partly to differences in lycopene absorption, since 
lycopene  (a  carotenoid  previously  associated  with  a  protective  effect  for  prostate  cancer)  is 
absorbed more readily from cooked, rather than raw tomatoes. These results also provide support 
that omega-3 fatty acid intakes may be protective, as well as vegetable consumption overall. 
 
Obesity and functional foods: An increasing number of studies strongly support that obesity-
induced inflammation plays an important role in the development of obesity-related pathologies. 
Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κ B) and c-Jun N-terminal 
kinases (JNK), the stress-activated protein kinase, are important modulators of inflammatory 
gene expression downstream of Toll-like receptor 4 (TLR4) in obese adipose tissues, which are 
regulated  by  peroxisome  proliferator-activated  receptor  gamma  (PPARγ)  [67].  In  particular, 
PPARγ  agonists  can  directly  reduce  adipocyte  size  and  induce  the  expression  of  anti-
inflammatory cytokines, such as adiponectin [68]. Many foods components including Abietic 
acid (Pine rosin), Auraptene (Citrus Fruit), Capsaicin (Hot pepper), Dehydroabietic acid (Pine 
rosin), Isohumulone Humulus (lupulus hop), Isoprenoid (Herb), Resveratrol (Red wine) and 6-
Shogaol  (Ginger)  reduce  obesity-induced  inflammatory  responses  by  suppressing  the 
inflammatory signalling in a PPARγ –dependent. Other dietary supplements act independently of 
PPARy  but  have  an  important  anti-inflammatory  role  in  the  control  of  obesity  and  are 
represented  by  Anthocyanin  (Red/PurplishFruit),  Diosgenin  Fenugreek  (Yam),  6-Gingerol 
(Ginger) and Luteolin Herb (Spice) [67,68]. 
A recent review published by Choudhary M and Grover K [69] confirmed the favourable 
role of functional foods in management of obesity. Authors proposed several nutrients basing on 
recent  studies  including  low-glycemic-index  carbohydrates,  5-hydroxytryptophan,  green  tea 
extract and chromium that have been shown to promote weight loss.  
 
Conclusions:  Obese  patients  have  numerous  biological  alterations  that  provoke  the 
aggressiveness of prostate cancer. However, obesity is a modifiable risk factor of prostate cancer.  
Several studies have demonstrated the positive impact of nutrition on prostate cancer. But, 
the role of functional foods in the management of prostate cancer needs to be clarified through 
large epidemiological studies. Recent studies provide strong evidence of the positive role of 
regular activity, reduce caloric intake, functional foods and bariatric surgery for obesity-related 
pathologies control. 
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TLR4= Toll-like receptor 4 
TNF-a= Tumor necrosis factor alpha 
WHO=World Health Organization 
WHR= Waist-to-hip 
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